Reunion Neuroscience
Reunion Neuroscience
Categories
Pharmaceutical
About
Reunion Neuroscience is a clinical stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.
The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.
Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.
Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.